問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


China Medical University Hospital (在職)

Division of Family Medicine

Division of General Internal Medicine

Division of Endocrinology

Division of Cardiovascular Diseases

更新時間：2023-09-19

林文元Lin, Wen-Yuan
  • Principal Investigator
  • Clinical Trial Experience (year) 12 years 9 個月

  • D10648@mail.cmuh.org.tw

Recruiting Trial

10Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

林文元

China Medical University Hospital

Division of Family Medicine

List

26Cases

2021-04-30 - 2022-07-14

Phase II

Completed
A 26-WEEK, PHASE 2B, 2-PART, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-06882961 ADMINISTRATION IN ADULTS WITH OBESITY

  • Condition/Disease

    Efficacy and safety of obese adults

  • Test Drug

    PF-06882961

Participate Sites
3Sites

Not yet recruiting1Sites

Terminated2Sites

2021-06-14 - 2022-05-13

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2024-10-01 - 2026-12-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2014-01-01 - 2015-02-27

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2023-01-30 - 2026-01-26

Phase II

Active
A Phase 2 Randomized, Placebo-controlled, Double-blind, Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus

  • Condition/Disease

    Obesity

  • Test Drug

    皮下注射劑

Participate Sites
4Sites

Recruiting4Sites

2023-12-29 - 2027-03-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2023-09-01 - 2026-06-30

Phase III

Active
A Phase 3/3b, Randomized, Observer-blind, Multicenter Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Subunit Inactivated Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age

  • Condition/Disease

    NA

  • Test Drug

    intramuscular injection

Participate Sites
5Sites

Recruiting5Sites

2022-11-21 - 2023-12-20

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2024-09-01 - 2026-09-01

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting4Sites

2021-04-01 - 2024-12-03

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB